Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none (as of 2024)
|
| gptkbp:CASNumber |
1609400-44-7
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2024)
|
| gptkbp:developedBy |
CymaBay Therapeutics
|
| gptkbp:hasInChIKey |
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C24H26ClNO2
|
| gptkbp:hasSMILES |
CC1=CC=CC=C1C(=O)C2=CC(=C(C=C2)Cl)NC3=C(C=CC=C3C)C
|
| gptkbp:hasUNII |
6Z1Y2V4S2E
|
| https://www.w3.org/2000/01/rdf-schema#label |
Seladelpar
|
| gptkbp:investigatedBy |
gptkb:nonalcoholic_steatohepatitis
gptkb:primary_biliary_cholangitis dyslipidemia |
| gptkbp:IUPACName |
2-chloro-4-[(2,6-dimethylphenyl)amino]phenyl]-(2-methylphenyl)methanone
|
| gptkbp:mechanismOfAction |
PPAR-delta agonist
|
| gptkbp:molecularWeight |
395.92 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2103887 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
MBX-8025
RWJ-800025 |
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|